These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37625479)

  • 1. Strengthening the case for BMP inhibition as a point of intervention for osteoarthritis.
    Lyons KM; Rosen V
    Osteoarthritis Cartilage; 2023 Nov; 31(11):1423-1424. PubMed ID: 37625479
    [No Abstract]   [Full Text] [Related]  

  • 2. Resemblance of osteophytes in experimental osteoarthritis to transforming growth factor beta-induced osteophytes: limited role of bone morphogenetic protein in early osteoarthritic osteophyte formation.
    Blaney Davidson EN; Vitters EL; van Beuningen HM; van de Loo FA; van den Berg WB; van der Kraan PM
    Arthritis Rheum; 2007 Dec; 56(12):4065-73. PubMed ID: 18050218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential drug targets within bone morphogenetic protein signaling pathways.
    Gazzerro E; Minetti C
    Curr Opin Pharmacol; 2007 Jun; 7(3):325-33. PubMed ID: 17475557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of bone morphogenetic proteins in kidney disease.
    Yanagita M
    Curr Opin Investig Drugs; 2010 Mar; 11(3):315-22. PubMed ID: 20178045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of bone morphogenetic proteins and cartilage-derived morphogenetic proteins during osteophyte formation in humans.
    Zoricic S; Maric I; Bobinac D; Vukicevic S
    J Anat; 2003 Mar; 202(Pt 3):269-77. PubMed ID: 12713267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts.
    Tardif G; Hum D; Pelletier JP; Boileau C; Ranger P; Martel-Pelletier J
    Arthritis Rheum; 2004 Aug; 50(8):2521-30. PubMed ID: 15334466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological exercise loading suppresses post-traumatic osteoarthritis progression via an increase in bone morphogenetic proteins expression in an experimental rat knee model.
    Iijima H; Ito A; Nagai M; Tajino J; Yamaguchi S; Kiyan W; Nakahata A; Zhang J; Wang T; Aoyama T; Nishitani K; Kuroki H
    Osteoarthritis Cartilage; 2017 Jun; 25(6):964-975. PubMed ID: 27965139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis.
    Bramlage CP; Häupl T; Kaps C; Ungethüm U; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR
    Arthritis Res Ther; 2006; 8(3):R58. PubMed ID: 16542506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN.
    Reddi AH
    Arthritis Res; 2001; 3(1):1-5. PubMed ID: 11178121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis.
    Derwall M; Malhotra R; Lai CS; Beppu Y; Aikawa E; Seehra JS; Zapol WM; Bloch KD; Yu PB
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):613-22. PubMed ID: 22223731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jun activation domain-binding protein 1 binds Smad5 and inhibits bone morphogenetic protein signaling.
    Haag J; Aigner T
    Arthritis Rheum; 2006 Dec; 54(12):3878-84. PubMed ID: 17133595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis.
    Scharstuhl A; Vitters EL; van der Kraan PM; van den Berg WB
    Arthritis Rheum; 2003 Dec; 48(12):3442-51. PubMed ID: 14673995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMP and BMP inhibitors in bone.
    Rosen V
    Ann N Y Acad Sci; 2006 Apr; 1068():19-25. PubMed ID: 16831902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
    Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
    J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Historical background and recent advance in BMP research].
    Yamaguchi A
    Clin Calcium; 2006 May; 16(5):732-37. PubMed ID: 16679613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of bone morphogenetic proteins, cartilage-derived morphogenetic proteins and related receptors in normal and osteoarthritic human articular cartilage.
    Bobinac D; Spanjol J; Marinović M; Zoricić Cvek S; Marić I; Cicvarić T; Fuckar D; Markić D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():83-7. PubMed ID: 19138012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis.
    Ahn J; Serrano de la Pena L; Shore EM; Kaplan FS
    J Bone Joint Surg Am; 2003 Apr; 85(4):667-74. PubMed ID: 12672843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of murine preosteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation.
    van der Horst G; van Bezooijen RL; Deckers MM; Hoogendam J; Visser A; Löwik CW; Karperien M
    Bone; 2002 Dec; 31(6):661-9. PubMed ID: 12531559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation.
    Otani H; Otsuka F; Inagaki K; Takeda M; Miyoshi T; Suzuki J; Mukai T; Ogura T; Makino H
    Am J Physiol Renal Physiol; 2007 May; 292(5):F1513-25. PubMed ID: 17244894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.
    Hover LD; Young CD; Bhola NE; Wilson AJ; Khabele D; Hong CC; Moses HL; Owens P
    Cancer Lett; 2015 Nov; 368(1):79-87. PubMed ID: 26235139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.